For an adult on chronic hemodialysis presenting with weeks of cough, episodic palpitations, persistent hypertension (~180/90 mm Hg) during dialysis sessions, and anxiety attacks, is sublingual clonidine 75 µg appropriate and what other pharmacologic and non‑pharmacologic management steps should be taken?

Management of Intradialytic Hypertension, Palpitations, Cough, and Anxiety in a Hemodialysis Patient

Do NOT Give Sublingual Clonidine 75 mcg

Clonidine is not dialyzable and its plasma concentration does not change significantly during hemodialysis; therefore, acute sublingual dosing is not an effective strategy for intradialytic hypertension. 1 Additionally, adding any antihypertensive agent during active ultrafiltration can precipitate dangerous intradialytic hypotension in this high-risk population. 2

---

Immediate Assessment Required

Cardiovascular Evaluation for Palpitations

• Obtain a 12-lead ECG immediately to rule out myocardial ischemia or arrhythmias, as dialysis patients often present with atypical cardiac symptoms and cardiac disease accounts for ~50% of dialysis-related deaths. 2
• Measure cardiac troponin when palpitations accompany a hypertensive episode. 2
• Do not dismiss palpitations as "only anxiety" without thorough cardiovascular workup—approximately 45% of dialysis patients experience anxiety that manifests as palpitations, but cardiac pathology must be excluded first. 2

Blood Pressure Context

• Your BP of 180/90 mmHg does NOT constitute a hypertensive emergency. Cardiovascular events in dialysis patients rise markedly only when systolic pressure approaches ≥180 mmHg, and both markedly high (>180 mmHg systolic) and markedly low (<110 mmHg systolic or <70 mmHg diastolic) predialysis pressures are associated with increased mortality. 1, 2

---

Immediate Dialysis Session Management

Volume Assessment and Ultrafiltration Adjustment

• Temporarily reduce or pause ultrafiltration if you appear volume-depleted, as rapid fluid removal can trigger paradoxical hypertension via sympathetic activation. 2
• Avoid aggressive ultrafiltration rates—keep UF ≤6 mL/h/kg to maintain hemodynamic stability. 2
• Do not administer antihypertensive medications during active ultrafiltration without first evaluating volume status and cardiac function. 2

Cough Evaluation

• Assess for ACE inhibitor-induced cough, which occurs in 5–10% of patients and is characterized by a nonproductive, persistent tickle in the throat. 1
• Evaluate for gastroesophageal reflux disease (GERD), as cough is significantly more common in dialysis patients (22% prevalence) and GERD is a major contributor due to volume shifts and medication effects. 1
• Rule out pulmonary edema from volume overload, which is a common cause of cough in this population. 1

---

Long-Term Management Strategy

Step 1: Optimize Volume Control FIRST (Most Critical)

• Reassess target dry weight over the next 4–12 weeks, as chronic volume overload is the most frequent driver of dialysis-associated hypertension. 1, 2
• Restrict dietary sodium to <5.8 g/day (ideally 2–3 g/day) to lessen thirst and interdialytic weight gain. 2
• Limit interdialytic weight gain to <3% of body weight between sessions. 2
• Extend each dialysis session to a minimum of 4 hours and slow ultrafiltration rates to improve hemodynamic stability. 2

Step 2: Dialysis Prescription Modifications

• Lower dialysate temperature to 34–35°C, which reduces symptomatic complications from 44% to 34%. 2
• Implement early-session sodium profiling with dialysate sodium ≈148 mEq/L to mitigate intradialytic symptoms. 2

Step 3: Pharmacologic Antihypertensive Therapy (Only After Volume Optimization)

• Add calcium-channel blockers (e.g., amlodipine) and β-blockers (e.g., carvedilol, labetalol) as second- and third-line agents when predialysis BP remains >140/90 mmHg after dry-weight optimization. 1, 2
• Choose non-dialyzable β-blockers (e.g., carvedilol, labetalol) over highly dialyzable ones (e.g., atenolol, metoprolol) to preserve intradialytic protection against arrhythmias. 1
• Consider ACE inhibitors or ARBs (benazepril, fosinopril) if not already prescribed, as they reduce left ventricular hypertrophy and are associated with decreased mortality. 1, 3
• If cough is confirmed to be ACE inhibitor-related and persistent, switch to an ARB (though angioedema risk exists with ARBs as well). 1

---

Anxiety and Palpitations Management

Non-Pharmacologic Interventions (First-Line)

• Implement cognitive-behavioral therapy (CBT) or mindfulness-based interventions, which have been shown to reduce anxiety symptoms in hemodialysis patients. 2, 4
• Offer music therapy during dialysis sessions, which can lower anxiety levels and improve pain perception. 2
• Encourage moderate-intensity physical activity for at least 150 minutes per week according to your ability, as aerobic exercise decreases depressive and anxiety symptom burden. 4

Pharmacologic Considerations (Use With Extreme Caution)

• Selective serotonin reuptake inhibitors (SSRIs) should be used cautiously, as they have heightened gastrointestinal adverse effects (nausea occurs 2.67 times more frequently than placebo) and limited evidence of benefit over placebo in dialysis patients. 2, 4
• Benzodiazepines are NOT recommended for routine intradialytic anxiety; they should be reserved for severe, refractory cases under specialist supervision. 2
• Screen regularly for depression and anxiety using validated instruments (Beck Depression Inventory, SF-36), as these conditions affect 25–50% of dialysis patients. 2, 4

---

Critical Pitfalls to Avoid

• Do not give indiscriminate saline boluses for blood-pressure control, as this worsens volume overload. 2
• Do not continue a twice-weekly dialysis schedule if you have recurrent intradialytic symptoms, because it forces dangerously high ultrafiltration rates. 2
• Do not add antihypertensive agents before correcting volume overload—this is the most common error and typically results in ineffective polypharmacy. 3
• Do not prescribe SSRIs as first-line treatment without first optimizing dialysis adequacy, correcting anemia, and attempting non-pharmacological interventions. 4

---

Monitoring and Follow-Up

• Measure home or interdialytic ambulatory BP over the next 2 weeks to accurately assess hypertension control, as HD unit BP values have poor agreement with ambulatory BP. 5, 6
• Ensure adequate dialysis delivery (minimum three times weekly) and achieve target dry weight, as inadequate dialysis contributes to both hypertensive and depressive symptoms. 4
• Correct anemia to recommended ranges, as this directly impacts overall well-being and quality of life. 4
• Review all medications for side effects that may contribute to cough, palpitations, or anxiety symptoms. 4